![]()
MIRA INFORM
REPORT
|
Report Date : |
18.01.2011 |
IDENTIFICATION DETAILS
|
Name : |
FRIENDS PHARMA (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishment : |
1993 |
|
|
|
|
Com. Reg. No.: |
0029342 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment
Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2010
|
Country Name |
Previous Rating (01.04.2010) |
Current Rating (30.06.2010) |
|
|
b2 |
b2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
FRIENDS PHARMA (PRIVATE) LIMITED
|
Registered
Address |
|
|
|
Tel # |
92 (42) 35935121, 35935122 |
|
Fax # |
92 (42) 35935123 |
|
Email |
|
a. |
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1993 |
|
c. |
Registration # |
0029342 |
|
Address |
5/39, Lower Mall, Near Session Courts, |
|
Tel # |
92 (42) 37240971 - 73 (3 Lines) |
|
Fax # |
92 (42) 37114410 |
Nazir Ahmad Chaudhri
(Chartered
Accountants)
Subject Company was established as a Private Limited Company in 1993
|
Authorized Capital |
Rs. 11,000,000/-
divided into 1,100,000 shares of Rs. 10/- each |
|
Issued & Paid up Capital |
Rs. 1,000,000/-
divided into 100,000 shares of Rs. 10/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Nadeem Zafar Mr. Muhammad Iqbal Khan Mr. Abubakar Yousaf Mrs. Sajeela Sarwar |
Pakistani Pakistani Pakistani Pakistani |
14-C, Aibak Block,
New 14-C, Aibak Block,
New 14-C, Aibak Block,
New 14-C, Aibak Block,
New |
Business Business Business Business |
Chief Executive Director Director Director |
|
Names |
|
Mr. Nadeem Zafar Mr. Muhammad Iqbal Khan Mr. Abubakar Yousaf Mrs. Sajeela Sarwar |
A. Subsidiary
None
B. Associated
Companies
(1) Shannza (Private) Limited,
Manufacture & marketing of Pharmaceutical Products by its brand names of ARTEMOSE, ARTISAF, BECLOTRIM, BEPRONATE, BETAMYCIN, BRAINAMAX, C-DOXIME, CEDRATE, CEFAROXIN, CEFROXIL, CIPFEN, COBAMIN, DERMICON, FAMCET, FLEXOREN, FLUFEND, FLURASAID, FRELEXIN, FRENDCOGEN, FRENDIK-P, FRENDIK-S, FROXTIN, GYTRIM, GYTRIM HC,INSTAZIN, INTEFRED, LEVOFEND, LIMICHOL, LORTAMINE, LOZAK, MEPRIUM, NIDACON, PANGIT, PEPROZOL, PILOXIN, PLANODERM, PREZIT, PRISM, PROFER, SIMPID, TELUKAST, ULCOZOL, VIOCEF, VIOXIME
86
The capacity and production of the company’s plant is
indeterminable as it involves varying processes of manufacture.
|
Year |
In Pak Rupees |
|
2009 |
120,000,000/- (Estimated) |
Mainly exist at all major cities including Interior Sindh & Interior Punjab Areas
· Habib Bank Limited, Pakistan.(Mortgage obtained PKR 60,000,000/-)
·
The Bank of
·
Standard Chartered
·
·
|
Currency |
Unit |
Pakistani
Rupee |
|
US Dollar |
1 |
Rs. 86.00 |
|
|
1 |
Rs. 135.74 |
|
Euro |
1 |
Rs. 113.81 |
Subject Company was established in 1993 and is engaged in manufacture & marketing of Pharmaceutical Products. Market reputation is good. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms & conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.59 |
|
|
1 |
Rs.72.31 |
|
Euro |
1 |
Rs.60.73 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this report.
The assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.